Skip to search formSkip to main contentSkip to account menu

C 1311

Known as: C-1311, C1311 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Aminoacridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
DNA-Damaging Imidazoacridinone C-1311 Induces Autophagy followed by Irreversible Growth Arrest and Senescence in Human Lung Cancer Cells
Imidazoacridinone 5-diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor inhibitor of topoisomerase II and… 
2012
2012
Role of Human UDP-Glucuronosyltransferases in the Biotransformation of the Triazoloacridinone and Imidazoacridinone Antitumor Agents C-1305 and C-1311: Highly Selective Substrates for UGT1A10
5-Diethylaminoethylamino-8-hydroxyimidazoacridinone, C-1311 (NSC-645809), is an antitumor agent shown to be effective against… 
2011
2011
The Imidazoacridinone Antitumor Drug, C-1311, Is Metabolized by Flavin Monooxygenases but Not by Cytochrome P450s
5-Diethylaminoethylamino-8-hydroxyimidazoacridinone (C-1311) is an antitumor agent that is also active against autoimmune… 
2011
2011
Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis
Antitumor imidazoacridinone C-1311 is a DNA-reactive topoisomerase II and FLT3 receptor tyrosine kinase inhibitor. Here, we… 
2008
2008
Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer
1055 Background: C1311 was designed from mitoxantrone to lessen cardiotoxicity. Although an inhibitor of topo II, its locus of… 
2007
2007
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines.
The cytotoxic activity of the imidazoacridinone C1311 was related to its effect on cell cycle progression in 16 human cell lines… 
2006
2006
The imidazoacridinone, C-1311 (Symadex™): The first of a potent new class of FLT3 inhibitors
B35 Background: C-1311 (Symadex™) is the lead compound in clinical development from a new series of agents, the… 
2005
2005
Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility
C1311 is the lead compound from the imidazoacridinones, a novel group of rationally designed anti-cancer agents. The compound is… 
2005
2005
Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
2002
2002
Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)